1. Germany Stocks

  2. •

    Commercial services

  3. •

    Miscellaneous commercial services
Vivoryon Therapeutics N.V.

Vivoryon Therapeutics N.V.

0.89
EUR
-0.02
(-2.61%)
32.13MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
0.54
- -
-0.14
- -
- -
- -
Basic EPS, GAAP
-1.35
-2.31
-1.93
-1.79
-0.96
-0.94
-0.62
-0.83
-0.63
-1.28
-1.12
-0.79
-0.33
- -
Free Cash Flow per Basic Share
-1.17
-2.14
-1.73
-1.72
-1.45
-0.85
-0.93
-0.73
-0.56
-0.99
-0.87
-0.74
-0.31
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.79
2.31
2.13
1.96
1.07
0.15
2.14
1.31
0.83
1.1
1.01
0.3
0.16
0.05
Tangible Book Value per Share
-0.81
2.29
2.11
1.94
1.06
0.15
2.14
1.28
0.8
1.08
0.97
0.27
0.13
0.03
Basic Weighted Avg Shares
7
5
7
8
8
8
13
20
20
22
25
26
27
29
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
11
- -
-4
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
-119.83
- -
795.44
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-10
-11
-14
-14
-8
-8
-8
-17
-13
-28
-28
-21
-9
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
-117.57
- -
782.93
- -
- -
- -
Working Capital
-3
17
17
17
10
3
44
27
15
27
27
9
6
2
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
-4
16
16
16
9
1
43
26
17
27
26
8
5
2
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
-84.13
-85.46
-63.31
-152.41
-35.64
-47.93
-59.17
-130.77
-107.38
-120.41
-140.45
- -

Capital Structure

EUR

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
26
30
30
Market Capitalization
38
43
32

Working Capital

EUR

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
5
6
3
Cash, Cash Equivalents & STI
5
6
3
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
1
1
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
311.23%
-17.53%
-40.01%
Free Cash Flow
5.29%
0.49%
-55.88%
Net Income, GAAP
8.47%
3.08%
-56.96%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.79
2025
- -
- -
-0.33
2026
- -
- -
- -

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Frank T. Weber
Full Time Employees
16
Sector
Commercial services
Industry
Miscellaneous commercial services
Address
Weinbergweg 22 Halle SA Germany 06120
IPO Date
Oct 27, 2014
Website
vivoryon.com
Similar Companies
PayPal Holdings, Inc. (NASDAQ:PYPL)
Shopify Inc. (NASDAQ:SHOP)
Greenland Mines Ltd (NASDAQ:GRML)
Block, Inc. (NYSE:XYZ)
Netcapital Inc. (NASDAQ:NCPL)
Shopify, Inc. Class A (TSX:SHOP)
Business
Vivoryon Therapeutics N.V. (VVY.AS) is a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting pathological toxic protein aggregation, primarily for Alzheimer's disease and other neurodegenerative disorders. The company offers a pipeline of small molecule inhibitors, including varoglutamstat (PQ912), a glutaminyl cyclase inhibitor in Phase 2 clinical trials for Alzheimer's disease; and HMTM (hydromethylthionine mesylate), an oral tau aggregation inhibitor advanced for Alzheimer's and Parkinson's disease treatment. Its research and development activities encompass discovery, preclinical studies, and clinical trials conducted through contract research organizations; services include biomarker development and patient stratification technologies based on proprietary pyroglutamate biomarkers. Vivoryon Therapeutics N.V., founded in 1997 and headquartered in Halle, Germany, operates primarily in Europe with clinical trial sites across multiple countries including Germany, the Netherlands, and Poland, targeting patients with neurodegenerative conditions through partnerships with academic institutions and contract manufacturers. In recent developments, the company completed patient recruitment for its Phase 2 VIVIAD trial of varoglutamstat in early Alzheimer's disease in 2023, with topline data expected in the first half of 2025; it also initiated the Phase 2b MERIDIAN trial for Parkinson's disease in collaboration with global contract research organizations. Vivoryon announced a strategic pipeline prioritization in 2024, focusing resources on varoglutamstat while deprioritizing earlier-stage assets to extend cash runway into 2026 following a capital raise of approximately EUR 12 million through equity financing. No major acquisitions, name changes, or reorganizations have occurred in the last two years, with operations remaining centered on its core neurodegeneration franchise.